diclofenac and rilpivirine

diclofenac has been researched along with rilpivirine in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's3 (100.00)2.80

Authors

AuthorsStudies
Chen, CH; Cherukupalli, S; Cocklin, S; De Clercq, E; Dick, A; Ding, X; Gao, P; Huang, T; Kang, D; Lee, KH; Liu, X; Meuser, ME; Pannecouque, C; Sun, L; Xu, S; Zalloum, WA; Zhan, P1
Daelemans, D; De Clercq, E; Gao, P; Ginex, T; Huang, B; Jiang, X; Kang, D; Liu, X; Luque, FJ; Pannecouque, C; Zhan, P; Zhang, J1
Chen, FE; De Clercq, E; Huang, WJ; Jin, X; Pannecouque, C; Wang, S; Zhang, YX; Zhao, LM1

Other Studies

3 other study(ies) available for diclofenac and rilpivirine

ArticleYear
Design, Synthesis, and Mechanism Study of Benzenesulfonamide-Containing Phenylalanine Derivatives as Novel HIV-1 Capsid Inhibitors with Improved Antiviral Activities.
    Journal of medicinal chemistry, 2020, 05-14, Volume: 63, Issue:9

    Topics: Animals; Anti-HIV Agents; Capsid Proteins; Cell Line, Tumor; Drug Design; Female; HIV-1; HIV-2; Humans; Male; Mice; Microsomes, Liver; Molecular Structure; Phenylalanine; Rats, Sprague-Dawley; Structure-Activity Relationship; Sulfonamides; Virus Replication

2020
Structure-Based Design and Discovery of Pyridyl-Bearing Fused Bicyclic HIV-1 Inhibitors: Synthesis, Biological Characterization, and Molecular Modeling Studies.
    Journal of medicinal chemistry, 2021, 09-23, Volume: 64, Issue:18

    Topics: Anti-HIV Agents; Cell Line; Drug Design; Heterocyclic Compounds, 2-Ring; HIV Reverse Transcriptase; HIV-1; Humans; Microsomes, Liver; Molecular Dynamics Simulation; Molecular Structure; Mutation; Protein Binding; Pyridines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship

2021
Structure-Based Discovery of Novel NH
    Journal of medicinal chemistry, 2022, 06-23, Volume: 65, Issue:12

    Topics: Anti-HIV Agents; Biphenyl Compounds; Drug Design; Heterocyclic Compounds, 1-Ring; HIV Reverse Transcriptase; HIV-1; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship

2022